DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ladostigil
Ladostigil
Novel Neuroprotective Compunds for Use in Parkinson's Disease
Treatment Protocol Copyright © 2018 Kostoff Et Al
WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
Avraham Pharmaceuticals Ltd. Protocol Number: CO17730
WO 2014/125397 Al 21 August 2014 (21.08.2014) P O P C T
(12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub
Caffeine Analogues and Their Evaluation As Inhibitors of Monoamine Oxidase And
Lessons Learned
Design, Synthesis and Evaluation of Indole Derivatives As
Perspectives for New and More Efficient Multifunctional Ligands For
Botulinum Toxin
Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’S Disease
Effect of Capparis Spinosa L. on Cognitive Impairment Induced by D-Galactose in Mice Via Inhibition of Oxidative Stress
Therapeutics of Alzheimer's Disease: Past, Present and Future
Essential Oils As a Potential Neuroprotective Remedy for Age-Related Neurodegenerative Diseases: a Review
Magic Bullets Or Novel Multimodal Drugs with Various CNS Targets for Parkinson’S Disease?
Use of Anti-Connexin Agents for Enhancing the Therapeutic Effect of Acetylcholinesterase Inhibitor
On the Clinical Pharmacology of Reactive Oxygen Species
Top View
Shedding Light Into the Role of BDNF in the Pharmacotherapy of Parkinson’S Disease
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Assessment of Enzyme Inhibition: a Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs
Is It a European Car Or a Japanese Car? an ERP Study of Diagnostic Information Use in Visual Expertise
Structure-Function Properties of Hemp Seed Proteins and Protein-Derived Acetylcholinesterase-Inhibitory Peptides
Monoamine Oxidase MAO
WO 2010/135731 Al
The Impact of Crystallization Conditions on Structure-Based Drug Design: a Case Study on the Methylene Blue/Acetylcholinesterase Complex
Phytochemicals That Regulate Neurodegenerative Disease by Targeting Neurotrophins: a Comprehensive Review
Abordagens Diferentes, Um Único Objetivo: Compreender Os
Anti-Inflammatory and Neuroprotective Properties of Ladostigil and Its Primary Metabolites
Cholinesterase Inhibitors As Alzheimer's Therapeutics (Review)
Screening and Evaluation of Natural Compounds for Therapeutic Application in Alzheimer’S Disease
Assessment of Enzyme Inhibition: a Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs
Management of Dementia-Related Psychosis, Agitation and Aggression
Letter from Idaho State University Regarding Two Personnel Changes
Phytochemicals That Regulate Neurodegenerative Disease by Targeting Neurotrophins: a Comprehensive Review
(12) Patent Application Publication (10) Pub. No.: US 2014/0243254 A1 Hersel Et Al
Table [1]: Definition of Reported Outcomes Study Outcome
Biological Assessment of Novel Series of Multitarget-Directed Ligands Based on Donepezil to Be Used In
Customs Tariff - Schedule
(12) Patent Application Publication (10) Pub. No.: US 2014/0296257 A1 Hersel Et Al
Irene Bolea Tomás Phd Thesis
On the Clinical Pharmacology of Reactive Oxygen Species
Table S1. Five Drug Approved by The
Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’S and Alzheimer’S Diseases As Disease Modifying Agents
(12) United States Patent (10) Patent No.: US 9,045,498 B2 Brodney Et Al
Low-Dose Ladostigil for the Treatment of Mild Cognitive
Annual Report 2013
Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’S and Alzheimer’S Disorders?**
Download Author Version (PDF)
Ladostigil Attenuates the Oxidative and ER Stress in Human Neuroblast-Like SH-SY5Y Cells
Therapeutic Agents for Alzheimer's Disease
Ep 3160590 B1
Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline
In-Silico Identification of Potential Inhibitors Against Ache Using Cheminformatics Approach